Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study.
暂无分享,去创建一个
Peter A Fasching | Mahdi Rezai | Keyur Mehta | Christoph Thomssen | Bernd Gerber | M. Rezai | P. Fasching | T. Kühn | H. Tesch | S. Loibl | I. Bauerfeind | M. Untch | J. Blohmer | G. von Minckwitz | J. Huober | C. Jackisch | C. Hanusch | C. Thomssen | H. Eidtmann | M. Kaufmann | A. du Bois | B. Gerber | J. Hilfrich | K. Mehta | Gunter von Minckwitz | Hans Tesch | Sibylle Loibl | Michael Untch | Jörn Hilfrich | Jens-Uwe Blohmer | Jens Huober | Andreas du Bois | Manfred Kaufmann | Holger Eidtmann | Christian Jackisch | Thorsten Kühn | Ingo Bauerfeind | Claus Hanusch | Serban Dan Costa | S. Dan Costa
[1] W. McGuire,et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.
[2] M. Rezai,et al. Capecitabine in addition to anthracycline- and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] S. Loibl,et al. Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial. , 2008, Journal of the National Cancer Institute.
[4] K. Gelmon,et al. Pharmacokinetics, safety, and efficacy of trastuzumab administered every three weeks in combination with paclitaxel. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] Norman Wolmark,et al. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer:National Surgical Adjuvant Breast and Bowel Project Protocol B-27. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] Irene L Andrulis,et al. HER2 and responsiveness of breast cancer to adjuvant chemotherapy. , 2006, The New England journal of medicine.
[7] E. Winer,et al. Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] T. Fleming,et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.
[9] H. Bloom,et al. Histological Grading and Prognosis in Breast Cancer , 1957, British Journal of Cancer.
[10] J. Baselga,et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort , 2010, The Lancet.
[11] Fiona J Gilbert,et al. Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] Greg Yothers,et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. , 2005, The New England journal of medicine.
[13] A. Brufsky,et al. Phase II study of neoadjuvant docetaxel, vinorelbine, and trastuzumab followed by surgery and adjuvant doxorubicin plus cyclophosphamide in women with human epidermal growth factor receptor 2-overexpressing locally advanced breast cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] M. Dowsett,et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. , 2005, The New England journal of medicine.
[15] S. Loibl,et al. Intensified neoadjuvant chemotherapy in early-responding breast cancer: phase III randomized GeparTrio study. , 2008, Journal of the National Cancer Institute.
[16] P. Fasching,et al. Integrated meta-analysis on 6402 patients with early breast cancer receiving neoadjuvant anthracycline-taxane +/- trastuzumab containing chemotherapy. , 2009 .
[17] Terry L. Smith,et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] Hans-Peter Sinn,et al. Clinical response after two cycles compared to HER2, Ki-67, p53, and bcl-2 in independently predicting a pathological complete response after preoperative chemotherapy in patients with operable carcinoma of the breast , 2008, Breast Cancer Research.
[19] M. Berger,et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. , 2006, The New England journal of medicine.
[20] L. Sobin. International Union Against Cancer , 2002 .